Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Anthracycline-based chemotherapy can result in the development of a cumulative and
progressively developing cardiomyopathy. Doxorubicin is one of the most highly prescribed …

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American
Society of Clinical Oncology Clinical P Page 1 City of Hope, Duarte, CA; American Society …

Abstract Doxorubicin (DOX), or Adriamycin, an anthracycline antibiotic discovered
serendipitously as a chemotherapeutic drug several decades ago, is still one of the most …

Cardiovascular disease is a competing cause of death in patients with cancer with early-
stage disease. This elevated cardiovascular disease risk is thought to derive from both the …

The literature exploring the utility of advanced echocardiographic techniques (such as
deformation imaging) in the diagnosis and prognostication of patients receiving potentially …

Purpose Cardiovascular diseases (CVDs), including ischemic heart disease, stroke, and
heart failure, are well-established late effects of therapy in survivors of childhood and young …

Background Trastuzumab improves survival in the adjuvant treatment of HER-positive breast
cancer, although combined therapy with anthracycline-based regimens has been …

Background: Cardiovascular disease (CVD) is of increasing concern among breast cancer
survivors. However, the burden of this comorbidity in this group relative to the general …